Cell-free fetal DNA screening for detection of microdeletion syndromes: a cost-effectiveness analysis
Fetuses with genetic copy number variants are poorly detected through traditional prenatal screening. Microdeletions and duplications are clearly identified with diagnostic testing through chromosomal microarray, and screening of a select number of microdeletions has become available with cell-free...
Saved in:
Published in | The journal of maternal-fetal & neonatal medicine Vol. 34; no. 11; p. 1732 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
03.06.2021
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Fetuses with genetic copy number variants are poorly detected through traditional prenatal screening. Microdeletions and duplications are clearly identified with diagnostic testing through chromosomal microarray, and screening of a select number of microdeletions has become available with cell-free DNA (cfDNA). Our study compares the costs and outcomes of cfDNA for five pathogenic microdeletions and aneuploidy to cfDNA for aneuploidy alone in conjunction with ultrasound.
A decision-analytic model was constructed using TreeAge software to compare cfDNA with microdeletions versus traditional cfDNA in a theoretical cohort of 4,000,000 pregnancies that would also be screened with ultrasound. Probabilities, costs, and utilities were derived from literature. The primary outcomes were the incremental cost per quality-adjusted life-year (QALY), terminations, and procedure-related losses. Because the microdeletion results are available, but not reported, on all cfDNA testing we set the incremental cost of the cfDNA microdeletion screening test to zero at baseline and varied the cost in sensitivity analysis.
Screening with cfDNA for microdeletions among all pregnant women would result in 83 fewer anomalous neonates compared to traditional cfDNA with ultrasound. This reduction is due to increased diagnosis and termination of fetuses with microdeletions in this group. Routine use of cfDNA with microdeletions resulted in more procedure-related losses. cfDNA with microdeletions would improve effectiveness by 977 QALYs and decrease costs by $90,991,784. When we varied the specificity of the screening test, we found that it remained cost-effective down to a specificity of 91%. With a threshold of $100,000/QALY, microdeletion screening is cost-effective to an incremental increase in cost over cfDNA for aneuploidy alone of $47.10.
For detection of fetal subchromosomal abnormalities, use of cfDNA with microdeletions is a cost-effective strategy compared to cfDNA for aneuploidy alone in conjunction with ultrasound. Cell-free DNA for microdeletions is not currently recommended as routine screening for low-risk obstetric populations by the American College of Obstetrics and Gynecologists or the Society for Maternal-Fetal Medicine. The test characteristics of cfDNA with microdeletions require greater examination before being routinely recommended. |
---|---|
AbstractList | Fetuses with genetic copy number variants are poorly detected through traditional prenatal screening. Microdeletions and duplications are clearly identified with diagnostic testing through chromosomal microarray, and screening of a select number of microdeletions has become available with cell-free DNA (cfDNA). Our study compares the costs and outcomes of cfDNA for five pathogenic microdeletions and aneuploidy to cfDNA for aneuploidy alone in conjunction with ultrasound.
A decision-analytic model was constructed using TreeAge software to compare cfDNA with microdeletions versus traditional cfDNA in a theoretical cohort of 4,000,000 pregnancies that would also be screened with ultrasound. Probabilities, costs, and utilities were derived from literature. The primary outcomes were the incremental cost per quality-adjusted life-year (QALY), terminations, and procedure-related losses. Because the microdeletion results are available, but not reported, on all cfDNA testing we set the incremental cost of the cfDNA microdeletion screening test to zero at baseline and varied the cost in sensitivity analysis.
Screening with cfDNA for microdeletions among all pregnant women would result in 83 fewer anomalous neonates compared to traditional cfDNA with ultrasound. This reduction is due to increased diagnosis and termination of fetuses with microdeletions in this group. Routine use of cfDNA with microdeletions resulted in more procedure-related losses. cfDNA with microdeletions would improve effectiveness by 977 QALYs and decrease costs by $90,991,784. When we varied the specificity of the screening test, we found that it remained cost-effective down to a specificity of 91%. With a threshold of $100,000/QALY, microdeletion screening is cost-effective to an incremental increase in cost over cfDNA for aneuploidy alone of $47.10.
For detection of fetal subchromosomal abnormalities, use of cfDNA with microdeletions is a cost-effective strategy compared to cfDNA for aneuploidy alone in conjunction with ultrasound. Cell-free DNA for microdeletions is not currently recommended as routine screening for low-risk obstetric populations by the American College of Obstetrics and Gynecologists or the Society for Maternal-Fetal Medicine. The test characteristics of cfDNA with microdeletions require greater examination before being routinely recommended. |
Author | Shaffer, Brian L Sparks, Teresa N Allen, Allison J Caughey, Aaron B Avram, Carmen M |
Author_xml | – sequence: 1 givenname: Carmen M surname: Avram fullname: Avram, Carmen M organization: Department of Obstetrics and Gynecology, Oregon Health & Sciences University, Portland, OR, USA – sequence: 2 givenname: Brian L surname: Shaffer fullname: Shaffer, Brian L organization: Department of Obstetrics and Gynecology, Oregon Health & Sciences University, Portland, OR, USA – sequence: 3 givenname: Teresa N surname: Sparks fullname: Sparks, Teresa N organization: Department of Obstetrics, Gynecology, and Reproductive Sciences, Univeristy of California San Francisco, San Francisco, CA, USA – sequence: 4 givenname: Allison J surname: Allen fullname: Allen, Allison J organization: Department of Obstetrics and Gynecology, Oregon Health & Sciences University, Portland, OR, USA – sequence: 5 givenname: Aaron B surname: Caughey fullname: Caughey, Aaron B organization: Department of Obstetrics and Gynecology, Oregon Health & Sciences University, Portland, OR, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31327283$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j9tKxDAYhIMo7kEfQckLtOZP0iT1blnXAyx6o9dLmvyRSpssTRX27d16uBrmY2ZgFuQ0poiEXAErgRl2A1IrzSpTcgZ1CUpqUHBC5hMvZF3JGVnk_MEYB8mqczITILjmRswJrrHrijAg0oCj7ejd84pmd_Sxje80pIF6HNGNbYo0Bdq3bkgeO_wB-RD9kHrMt9RSl_JYYAhT-Asj5kxttN0ht_mCnAXbZbz80yV5u9-8rh-L7cvD03q1LZxU5lgW4IMJygtUwHgt0BpfIxNN0JI5poNEV0MVhOFVo1ADQKMqJ6ejTjq-JNe_u_vPpke_2w9tb4fD7v8v_wbuq1lx |
CitedBy_id | crossref_primary_10_1002_pd_5700 crossref_primary_10_1002_pd_6357 crossref_primary_10_1152_physiolgenomics_00086_2020 crossref_primary_10_1016_j_gim_2022_11_004 crossref_primary_10_1093_humrep_dead033 crossref_primary_10_3389_fgene_2024_1390539 crossref_primary_10_1016_j_gim_2022_03_019 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1080/14767058.2019.1647161 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1476-4954 |
ExternalDocumentID | 31327283 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NICHD NIH HHS grantid: K12 HD001262 |
GroupedDBID | --- 00X 03L 0BK 0YH 123 29L 36B 3V. 4.4 53G 5RE 5VS 7RV 7X7 88E 8AO 8FI 8FJ AALIY AALUX AAMIU AAPUL AAQQT AAQRR AAWTL ABBKH ABEIZ ABJNI ABLIJ ABLKL ABUPF ABUWG ABXYU ACENM ACGEJ ACGFS ACKZS ADBBV ADCVX ADFOM ADFZZ ADRBQ ADXPE AECIN AEIIZ AENEX AEOZL AFKRA AFKVX AGDLA AGFJD AGRBW AGYJP AHMBA AIJEM AJWEG AKBVH ALIPV ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AMDAE AWYRJ BABNJ BENPR BKEYQ BLEHA BOHLJ BPHCQ BVXVI CAG CCCUG CCPQU CGR COF CS3 CUY CVF CZDIS DKSSO DRXRE DU5 DWTOO EBS ECM EIF EJD EMOBN EX3 F5P FYUFA H13 HMCUK HZ~ KRBQP KSSTO KWAYT KYCEM LGLTD LJTGL M1P M44 M4Z NAPCQ NPM NUSFT O9- PCD PQQKQ PROAC PSQYO RNANH RRB RVRKI RWL S0X TAE TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ UEQFS UKHRP V1S V2E WOW ~1N |
ID | FETCH-LOGICAL-c468t-e31df8f6d3e610293ea8d9e03bf740c07f4ec915f3825b6e7111b65c41476c4c2 |
IngestDate | Wed Oct 16 00:41:04 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | Cell-free DNA cost-effectiveness subchromosomal microdeletions ultrasound |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c468t-e31df8f6d3e610293ea8d9e03bf740c07f4ec915f3825b6e7111b65c41476c4c2 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000293 |
PMID | 31327283 |
ParticipantIDs | pubmed_primary_31327283 |
PublicationCentury | 2000 |
PublicationDate | 2021-06-03 |
PublicationDateYYYYMMDD | 2021-06-03 |
PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-03 day: 03 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | The journal of maternal-fetal & neonatal medicine |
PublicationTitleAlternate | J Matern Fetal Neonatal Med |
PublicationYear | 2021 |
SSID | ssj0021405 |
Score | 2.3746638 |
Snippet | Fetuses with genetic copy number variants are poorly detected through traditional prenatal screening. Microdeletions and duplications are clearly identified... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1732 |
SubjectTerms | Aneuploidy Cell-Free Nucleic Acids Cost-Benefit Analysis DNA Female Fetus Humans Infant, Newborn Pregnancy Prenatal Diagnosis Syndrome |
Title | Cell-free fetal DNA screening for detection of microdeletion syndromes: a cost-effectiveness analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31327283 |
Volume | 34 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELa2Rap6QeUNLcgHbpVLEtuxw221gKpK7IVW6q2ynbGQ2M2usgsH_hf_j7GdpKEtCFCkKLIjK_L3ZTIzmQchr2sPvMg0sKoWhglZWGa9UCwvpUP4NR4xyndenl6Is0t5OZn8GEUtfd3aE_f9zryS_0EVxxDXkCX7D8gOi-IAXiO-eEaE8fxXGM9gsWC-BTj2EJIa382nxygG0DTt4yNr2ILrlcJlCL4LjW_iQF-rYJPynd1qs2UpuqMXgKYrWDJWYAOtRtUmUN-NRaRZeoDAowaCQ75LShn_tp9-axP7ZqZdQjPqZPzZhC4tiWpB4AwO6U9r035JgUzQwsZc_ziahhYwKUNnEbsono39F0WKs0oyDZLMFapkaKeJsVDuPJwd-fKRiM1Vcojekv0pWDKspjIZo_aqk1AtLU_V3kd8WC8jIULVSlWkPjp_nr1Rkruf2iE7Sod-IfPgIuqsfLRYZZ8qprM3dz7PPtnr17hhzkS15vyA3O_sETpN5HpAJtA8JHsfO-geERg4RiPEFDlGB45R5BgdOEZXnv7CMTpw7C019DbDaM-wx-Tiw_vz2SnrWnMwJ0qNN_O89tqXNQfUv1FlBKPrCjJuvRKZy5QX4Kpceq4LaUtQ-Em1-PqLsB1OuOIJ2W1WDTwjNPOSV9zmVhlA3V7azHJZGZ1zURcl6Ofkadqgq3Wqv3LVb92L384ckv1rqh2Rex5feHiJ2uPWvopo_QQRQG2I |
link.rule.ids | 780 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cell-free+fetal+DNA+screening+for+detection+of+microdeletion+syndromes%3A+a+cost-effectiveness+analysis&rft.jtitle=The+journal+of+maternal-fetal+%26+neonatal+medicine&rft.au=Avram%2C+Carmen+M&rft.au=Shaffer%2C+Brian+L&rft.au=Sparks%2C+Teresa+N&rft.au=Allen%2C+Allison+J&rft.date=2021-06-03&rft.eissn=1476-4954&rft.volume=34&rft.issue=11&rft.spage=1732&rft_id=info:doi/10.1080%2F14767058.2019.1647161&rft_id=info%3Apmid%2F31327283&rft_id=info%3Apmid%2F31327283&rft.externalDocID=31327283 |